Smith & Nephew plc (LON:SN.)
77% of retail CFD accounts lose money.
|Dividend Rate (ttm)||0.2890|
|Trading Day||Jun 10|
|Day's Range||12.09 - 12.32|
|52 Week Range||11.51 - 16.01|
About Smith & Nephew plc
Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. It calls this purpose 'Life Unlimited'.
Its 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of its product portfolio, and the invention and application of new technologies across its three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, it now operates in more than 100 countries, and generated annual sales of $4.6 billion in 2020.
NewsNo news found.
Smith & Nephew plc dividends
Smith & Nephew plc has a market cap or net worth of £10.55 billion. The enterprise value is £0.
Smith & Nephew plc has 872.46 million shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is 0.0000. Smith & Nephew plc's PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.0652%. The beta is 0.0000, so Smith & Nephew plc's price volatility has been lower than the market average.
In the last 12 months, Smith & Nephew plc had revenue of £0 and earned £0 in profits. Earnings per share was £.